#USA #Philadelphia #WCG #Clario #eCOA

Clario Enhances Clinical Trial Capabilities through WCG Acquisition

Clario, a recognized leader in digital data solutions for clinical trials, has successfully completed the acquisition of WCG’s electronic clinical outcome assessment (eCOA) business. This strategic enhancement positions Clario to not only bolster its offerings but also significantly improve data collection and analysis capabilities within the neuroscience sector.

In a statement released on May 6, 2025, Clario expressed enthusiasm about integrating WCG’s eCOA team and technologies, marking a pivotal step toward becoming a frontrunner in endpoint data solutions tailored for neuroscience clinical trials. Chris Fikry, M.D., the CEO of Clario, articulated the potential of this merger: “Our clients will now have access to the most reliable, high-quality data across multiple modalities and all major neuroscience endpoints, addressing a vital area of unmet medical need.”

The acquisition of WCG’s eCOA capabilities aligns seamlessly with Clario’s recent efforts in expanding its expertise through the acquisition of NeuroRx, specialists in neurology imaging analysis. This integration emphasizes their commitment to developing best-in-class solutions for the complexities of clinical trials, which are integral in drug development processes. Clario aims to support its clients by delivering refined services in:

• - Study Design and Protocol Development: Crafting methodologies that align with the regulatory standards and best practices in clinical research.
• - Site Selection and Training: Ensuring that study sites are equipped and knowledgeable about protocol specifics to facilitate smooth trial operations.
• - Clinical Outcomes Assessments: Streamlining how patient responses are measured and interpreted to offer insightful data to developers.
• - Centralized Image Analysis: Leveraging advanced technologies to analyze medical images meticulously.
• - Cardiac Safety Expertise: Addressing the cardiovascular implications often critical in medical trials.
• - Quantitative Movement Analysis: Providing detailed assessments crucial in therapies targeted at neuromuscular conditions.
• - Regulatory Guidance: Offering expertise to navigate the complex landscape of clinical trial regulations.

Terry Burke, executive vice president of Clario’s eCOA segment, described the acquisition as a significant advancement within the clinical research landscape for neuroscience. The established framework and methodologies of the WCG team will continue operationally intact, ensuring an uninterrupted transition for ongoing trials. “This is a game-changer for clinical research in neuroscience,” he noted, highlighting how this will propel the company’s capability in supporting new complex studies and expedite breakthrough therapies.

Clario’s robust backing from notable private equity firms such as Astorg and Nordic Capital has helped galvanize its position in the sector since 2019. The enterprises’ joint support echoes a shared vision for growth and innovation in clinical trial solutions. Judith Charpentier and Daniel Berglund, both health sector co-heads at their respective firms, expressed excitement regarding this acquisition, underlining their confidence in Clario’s growth trajectory.

The integration of the WCG eCOA team and its established data collection strategies into Clario marks a new chapter in the firm’s journey. By harnessing advanced digital solutions and scientific rigor, Clario is set to enhance the research and therapeutic advancements in neuroscience.

As Clario charts its path ahead, it remains committed to its mission of transforming lives globally through high-quality clinical evidence. With over 50 years in operation and more than 26,000 endpoint data solutions deployed across 100+ countries, Clario's global expertise aims to continue influencing FDA drug approvals significantly.

For those interested in learning more about Clario and its innovative approaches, further information can be found on their official website Clario.com.